Xcellon Biologics
A specialized CDMO focused on development and manufacturing of complex biologics with emphasis on antibody–drug conjugates (ADCs) and bioconjugates. Services span lead selection, conjugation process development, downstream purification, analytical and formulation development, and predictive data analytics. The organization is expanding to offer GMP manufacturing and clinical supply capabilities in Maryland.
Industries
N/A
Nr. of Employees
small (1-50)
Services
Screening of linker–payload options and conjugation strategies, developability assessment, and generation of in vivo‑suitable material for preclinical evaluation.
Conjugation optimization, DoE, DAR control, platform DSP integration, and medium-scale generation of material for toxicology and IND-enabling studies.
Upstream and downstream process development, protein engineering, and process optimization to enable scale-up and technology transfer to manufacturing.
Identity, purity, potency, and stability testing paired with formulation optimization to establish release criteria and support regulatory submissions.
Integration of conjugation, purification, and stability datasets with predictive models and dashboards to forecast risks and support process decisions.
Planned clinical manufacturing services including GMP bioconjugation, integrated DSP, and upstream cell culture capacity to support clinical supply (facility readiness projected for 2026).
Screening of linker–payload options and conjugation strategies, developability assessment, and generation of in vivo‑suitable material for preclinical evaluation.
Conjugation optimization, DoE, DAR control, platform DSP integration, and medium-scale generation of material for toxicology and IND-enabling studies.
Upstream and downstream process development, protein engineering, and process optimization to enable scale-up and technology transfer to manufacturing.
Identity, purity, potency, and stability testing paired with formulation optimization to establish release criteria and support regulatory submissions.
Integration of conjugation, purification, and stability datasets with predictive models and dashboards to forecast risks and support process decisions.
Planned clinical manufacturing services including GMP bioconjugation, integrated DSP, and upstream cell culture capacity to support clinical supply (facility readiness projected for 2026).
Expertise Areas
- Antibody–drug conjugate (ADC) development
- Bioconjugation and site-specific conjugation
- Analytical and formulation development for complex biologics
- Bioprocess development and scale-up
Key Technologies
- Enzymatic glycan remodeling for site-specific conjugation
- Platform downstream purification (DSP)
- Conjugation chemistries: cysteine, lysine, click chemistry, enzyme-catalyzed methods
- DAR profiling and mass-based peptide mapping
News & Updates
Exhibit and present glycan-directed conjugation strategies and development services at World ADC 2025 (San Diego).
Announcement of a partnership to integrate external linker–payload chemistries into ADC development and scalable manufacturing workflows.
Collaboration to advance multispecific ADC programs combining multispecific antibody engineering with bioconjugation and scale-up expertise.
Award of $990,000 from TEDCO Equitech Growth Fund to support expansion of ADC biomanufacturing facility, including cleanrooms, labs, and digital connectivity for GMP readiness.
Exhibit and present glycan-directed conjugation strategies and development services at World ADC 2025 (San Diego).
Announcement of a partnership to integrate external linker–payload chemistries into ADC development and scalable manufacturing workflows.
Collaboration to advance multispecific ADC programs combining multispecific antibody engineering with bioconjugation and scale-up expertise.
Award of $990,000 from TEDCO Equitech Growth Fund to support expansion of ADC biomanufacturing facility, including cleanrooms, labs, and digital connectivity for GMP readiness.